Antibody-based drugs and vaccines against severe acute respiratory syndrome coronavirus
2 (SARS-CoV-2) are being expedited through preclinical and clinical development. Data …

As the coronavirus disease 2019 (COVID-19) pandemic evolves and vaccine rollout
progresses, the availability and demand for monoclonal antibodies for the prevention and …

While new vaccines for SARS-CoV-2 are authorized based on neutralizing antibody (nAb)
titer against emerging variants of concern, an analogous pathway does not exist for …

The newly emerged severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has
infected millions of people and caused tremendous morbidity and mortality worldwide …

Potent neutralizing monoclonal antibodies are one of the few agents currently available to
treat COVID-19. SARS-CoV-2 variants of concern (VOCs) that carry multiple mutations in the …

SARS-CoV-2 poses a public health threat for which therapeutic agents are urgently needed.
Herein, we report that high-throughput microfluidic screening of antigen-specific B-cells led …

Background Neutralizing-antibody (nAb) is the major focus of most ongoing COVID-19
vaccine trials. However, nAb response against SARS-CoV-2, when present, decays rapidly …

A newly identified novel coronavirus (SARS-CoV-2) is causing pneumonia-associated
respiratory syndrome across the world. Epidemiology, genomics, and pathogenesis of the …

A growing body of evidence shows that fragment crystallizable (Fc)-dependent antibody
effector functions play an important role in protection from severe acute respiratory …

Summary Coronavirus disease 2019 (COVID-19) has become a worldwide threat to
humans, and neutralizing antibodies have therapeutic potential. We have purified more than …